AdvaMed Welcomes ITC Report on U.S.-Mexico-Canada Trade Agreement
Apr. 19, 2019
WASHINGTON, D.C. – The Advanced Medical Technology Association (AdvaMed) issued the following statement from Ralph Ives, executive vice president, global strategy and analysis, following release of a report by the International Trade Commission (ITC) on the likely impact of the United States-Mexico-Canada Agreement (USMCA) on the U.S. economy and specific industry sectors, including the medical technology industry.
"AdvaMed welcomes the ITC report demonstrating the USMCA’s substantially positive impact on the U.S. economy compared to NAFTA. We are also very pleased that the ITC report identifies specific benefits for the medical technology industry, including transparency and procedural fairness for reimbursement, specific best practices for medical technology product approvals, good regulatory practices, customs and trade facilitation, and improved intellectual property protection. These new provisions will further regulatory harmonization across borders and foster expanded access to the latest medical technology innovations for the benefit of patients.
“In view of these clear benefits, we urge the U.S. Congress and the governments of Mexico and Canada to approve the USMCA as expeditiously as possible.”